U.S. markets open in 4 hours 43 minutes
  • S&P Futures

    4,151.50
    -32.00 (-0.76%)
     
  • Dow Futures

    34,496.00
    -172.00 (-0.50%)
     
  • Nasdaq Futures

    13,186.75
    -170.00 (-1.27%)
     
  • Russell 2000 Futures

    2,182.10
    -27.50 (-1.24%)
     
  • Crude Oil

    64.23
    -0.69 (-1.06%)
     
  • Gold

    1,836.30
    -1.30 (-0.07%)
     
  • Silver

    27.53
    +0.04 (+0.14%)
     
  • EUR/USD

    1.2161
    +0.0027 (+0.22%)
     
  • 10-Yr Bond

    1.6020
    0.0000 (0.00%)
     
  • Vix

    21.47
    +4.78 (+28.64%)
     
  • GBP/USD

    1.4122
    +0.0001 (+0.01%)
     
  • USD/JPY

    108.8500
    +0.0090 (+0.01%)
     
  • BTC-USD

    55,584.78
    -2,857.27 (-4.89%)
     
  • CMC Crypto 200

    1,473.45
    -87.85 (-5.63%)
     
  • FTSE 100

    6,974.86
    -148.82 (-2.09%)
     
  • Nikkei 225

    28,608.59
    -909.71 (-3.08%)
     

Phio Pharma's Intasyl Platform Shows Promising Tumor Control Activity In Animal Studies

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Phio Pharmaceuticals Corp (NASDAQ: PHIO) announced new preclinical data for the Intasyl platform in tumor settings.

  • These data were presented today during the AACR Annual Meeting 2021.

  • Data showed that local intratumoral (IT) delivery with the murine PD-1 targeting Intasyl (mPH-762) inhibits tumor growth in a dose-dependent fashion in PD-1 responsive and refractory animal models, compared to control-treated tumors.

  • Furthermore, on-target efficacy was supported by the modulation of immune cell populations toward antitumor phenotypes.

  • The company believes Intasyl mPH-762 can provide strong local immune checkpoint blockade (ICB) without the dose immune-related adverse effects (irAEs) seen with systemic ICB antibody therapy.

  • Phio is planning to start the first-in-human clinical study of PH-762 as a directly administered drug in patients with advanced melanoma, scheduled to begin by the end of this year.

  • Local intratumoral administration can mitigate dose-limiting systemic side effects. All Intasyl treatments were well tolerated.

  • See the AACR poster here.

  • Price Action: PHIO shares are down 1.8% at $2.69 in the premarket on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.